Miyamae Yohei, Takahashi Kengo, Igarashi Takamichi, Tanaka Kazumi, Takahashi Norifumi, Hirai Keitarou, Tsukagoshi Hiroshi, Ogawa Hiroomi, Yoshinari Daisuke, Sunose Yutaka, Takeyoshi Izumi
Dept. of Thoracic and Visceral Organ Surgery, Faculty of Medicine, Gunma University.
Gan To Kagaku Ryoho. 2014 Jun;41(6):737-41.
In recent years, there has been significant progress in systemic chemotherapy for metastatic or recurrent colorectal cancer. We investigated the clinical efficacy and feasibility of the bevacizumab and capecitabine /oxaliplatin(CapeOX)combination for untreated colorectal cancer. From October 2009 to June 2012, 38 patients were included, 18 receiving CapeOX alone and 20 receiving CapeOX plus bevacizumab. The response rate and disease-control rate were 16% and 5 0%, respectively, in the CapeOX arm, and 5 5% and 8 5%, respectively, in the CapeOX plus bevacizumab arm. Median progression-free survival was 8.0 months in the CapeOX arm and 1 2.8 months in CapeOX plus bevacizumab arm. The median overall survival was 21.6 months in the CapeOX arm and 3 4.0 months in CapeOX plus bevacizumab arm. Our results suggest that CapeOX treatment can be useful in the outpatient setting and more effective when combined with bevacizumab. Except in cases of bevacizumab intolerance, addition of bevacizumab to CapeOX treatment is considered useful as first-line therapy for metastatic or recur- rent colorectal cancer.
近年来，转移性或复发性结直肠癌的全身化疗取得了显著进展。我们研究了贝伐单抗与卡培他滨/奥沙利铂（CapeOX）联合用药治疗初治结直肠癌的临床疗效和可行性。2009年10月至2012年6月，共纳入38例患者，其中18例仅接受CapeOX治疗，20例接受CapeOX联合贝伐单抗治疗。CapeOX组的缓解率和疾病控制率分别为16%和50%，CapeOX联合贝伐单抗组分别为55%和85%。CapeOX组的无进展生存期中位数为8.0个月，CapeOX联合贝伐单抗组为12.8个月。CapeOX组的总生存期中位数为21.6个月，CapeOX联合贝伐单抗组为34.0个月。我们的结果表明，CapeOX治疗在门诊环境中可能有用，与贝伐单抗联合使用时更有效。除贝伐单抗不耐受的情况外，在CapeOX治疗中加用贝伐单抗被认为作为转移性或复发性结直肠癌的一线治疗是有用的。
